FI884280A - Menetelmä päällystetyn, hidastetun luovutuksen omaavan antomuodon valmistamiseksi - Google Patents

Menetelmä päällystetyn, hidastetun luovutuksen omaavan antomuodon valmistamiseksi Download PDF

Info

Publication number
FI884280A
FI884280A FI884280A FI884280A FI884280A FI 884280 A FI884280 A FI 884280A FI 884280 A FI884280 A FI 884280A FI 884280 A FI884280 A FI 884280A FI 884280 A FI884280 A FI 884280A
Authority
FI
Finland
Prior art keywords
component
preparing
dosage form
sustained release
release coated
Prior art date
Application number
FI884280A
Other languages
English (en)
Swedish (sv)
Other versions
FI95771C (fi
FI95771B (fi
FI884280A0 (fi
Inventor
Joel Sinnreich
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI884280A0 publication Critical patent/FI884280A0/fi
Publication of FI884280A publication Critical patent/FI884280A/fi
Application granted granted Critical
Publication of FI95771B publication Critical patent/FI95771B/fi
Publication of FI95771C publication Critical patent/FI95771C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inorganic Insulating Materials (AREA)
  • Glass Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Road Signs Or Road Markings (AREA)
FI884280A 1987-09-18 1988-09-16 Menetelmä päällystetyn, hidastetun luovutuksen omaavan antomuodon valmistamiseksi FI95771C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH362187 1987-09-18
CH362187 1987-09-18

Publications (4)

Publication Number Publication Date
FI884280A0 FI884280A0 (fi) 1988-09-16
FI884280A true FI884280A (fi) 1989-03-19
FI95771B FI95771B (fi) 1995-12-15
FI95771C FI95771C (fi) 1996-03-25

Family

ID=4259918

Family Applications (1)

Application Number Title Priority Date Filing Date
FI884280A FI95771C (fi) 1987-09-18 1988-09-16 Menetelmä päällystetyn, hidastetun luovutuksen omaavan antomuodon valmistamiseksi

Country Status (21)

Country Link
US (1) US4996058A (fi)
EP (1) EP0307904B1 (fi)
JP (1) JP2738936B2 (fi)
KR (1) KR960009408B1 (fi)
AT (1) ATE85518T1 (fi)
AU (1) AU618020B2 (fi)
CA (1) CA1331341C (fi)
DD (1) DD282392A5 (fi)
DE (1) DE3878361D1 (fi)
DK (1) DK516888A (fi)
ES (1) ES2040789T3 (fi)
FI (1) FI95771C (fi)
GR (1) GR3007695T3 (fi)
HU (1) HU208920B (fi)
IE (1) IE62990B1 (fi)
IL (1) IL87710A (fi)
MX (1) MX13023A (fi)
NO (1) NO178095C (fi)
NZ (1) NZ226210A (fi)
PT (1) PT88505B (fi)
ZA (1) ZA886873B (fi)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
ATE158180T1 (de) 1991-06-21 1997-10-15 Univ Cincinnati Oral verabreichbare therapeutische proteine und herstellungsverfahren
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
DK0603992T4 (da) * 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
AU2791295A (en) * 1994-06-24 1996-01-19 Ciba-Geigy Ag Method of determining the amount of active substance released from solid or semi-solid preparations administered to humans or animals
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
KR100503266B1 (ko) * 1997-01-14 2005-07-25 에르테에스 로만 테라피-시스테메 게엠베하 운트 코. 카게 위장관 내의 활성물질 방출을 조절하는, 팽창가능한 위장 체류성 치료장치
DE19822278A1 (de) * 1998-05-18 1999-12-02 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoff im Gastrointestinaltrakt mit verzögerter Pyloruspassage
WO2000001364A1 (en) * 1998-07-01 2000-01-13 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of thieno [3,2-c] pyridine derivatives
DE19837073A1 (de) * 1998-08-17 2000-03-23 Lohmann Therapie Syst Lts Folienförmige Wirkstoffträger
DE19850309A1 (de) * 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
DE19920833A1 (de) * 1999-05-06 2000-11-16 Lohmann Therapie Syst Lts Gastroretentives System mit quellbaren Polymeren
DE19920838A1 (de) * 1999-05-06 2000-11-16 Lohmann Therapie Syst Lts Gastroretentives System mit Kapillaren
DE19920835A1 (de) 1999-05-06 2000-11-16 Lohmann Therapie Syst Lts Verfahren und Vorrichtung zur Herstellung von Flachbett-Siegelrandbeuteln, enthaltend eine Zubereitung mit einem Gasbildner sowie ein nach dem Verfahren hergestellter Siegelrandbeutel
DE19920837A1 (de) * 1999-05-06 2000-11-16 Lohmann Therapie Syst Lts Gastroretentives System für verlängerte Verweilzeit im Magen bzw. im Gastrointestinaltrakt
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
GB0102725D0 (en) * 2001-02-02 2001-03-21 Stowic Resources Ltd Medical delivery system
EP1245227A1 (en) * 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
MXPA03011096A (es) * 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
JP4031232B2 (ja) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 新規カプセル
AU2002356719A1 (en) * 2001-12-17 2003-06-30 Gunther Beisel Agent for oral administration and method for producing the same
WO2003076513A1 (en) * 2002-03-04 2003-09-18 Buckley, Chad Improved polyvinyl alcohol film and method of producing the same
WO2004032906A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
DE602004004902T2 (de) * 2003-07-30 2007-11-15 Merrion Research I Ltd. Verfahren und Maschine für die automatische Herstellung von magensaftresistenten Kapseln
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20060003003A1 (en) * 2004-06-28 2006-01-05 Bakker Johan A Oral sustained release formulation of tedisamil with gastric retention properties
FR2873294B1 (fr) * 2004-07-26 2008-05-09 Greenpharma Sa Sa Association de medicaments
EP1786378A2 (en) * 2004-07-30 2007-05-23 Merrion Research II Limited Improved process and machine for automated manufacture of gastro-retentive devices
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
CA2584338C (en) * 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP5479086B2 (ja) 2006-03-16 2014-04-23 トリス・フアルマ・インコーポレーテツド 薬剤−イオン交換樹脂複合体を含有する放出調節製剤
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EA201300152A1 (ru) 2006-11-27 2013-07-30 Х. Лундбекк А/С Гетероариламидные производные
CA2673665C (en) 2006-12-22 2017-03-21 Ironwood Pharmaceuticals, Inc. Method and compositions for treating esophageal disorders
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
CA2689978A1 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102105136B (zh) 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
EP2326310B1 (en) * 2008-08-15 2019-05-15 Assertio Therapeutics, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012050922A2 (en) 2010-09-28 2012-04-19 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
BR112013017169A2 (pt) 2011-01-07 2016-10-04 Merrion Res Iii Ltd composições farmacêuticas de ferro para administração oral
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015274451C1 (en) 2014-06-11 2019-09-12 Massachusetts Institute Of Technology Residence structures and related methods
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CA2983272C (en) 2015-05-01 2023-08-29 Massachusetts Institute Of Technology Triggerable shape memory induction devices
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN108721246B (zh) * 2018-05-29 2021-06-25 王喆明 高分子材料构建的多单元超长效口服制剂及其制备方法
BR112020026266A2 (pt) 2018-06-19 2021-03-30 National University Of Singapore Formulações de 5-hidroxitriptofano (5-htp) para melhor biodisponibilidade para várias indicações
EP3897728A1 (en) * 2018-12-18 2021-10-27 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxyalkyl methylcellulose
BR112024001927A2 (pt) 2021-07-30 2024-04-30 Evecxia Therapeutics Inc Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901232A (en) * 1973-10-26 1975-08-26 Alza Corp Integrated device for administering beneficial drug at programmed rate
GB1518364A (en) * 1976-05-05 1978-07-19 Beecham Group Ltd Pharmaceutical composition
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
GB8305797D0 (en) * 1983-03-02 1983-04-07 Graham N B Hydrogel-containing envelopes
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子

Also Published As

Publication number Publication date
AU618020B2 (en) 1991-12-12
DD282392A5 (de) 1990-09-12
NO884134L (no) 1989-03-20
JP2738936B2 (ja) 1998-04-08
IL87710A (en) 1992-06-21
DE3878361D1 (de) 1993-03-25
HU208920B (en) 1994-02-28
EP0307904B1 (de) 1993-02-10
NO178095C (no) 1996-01-24
IE882829L (en) 1989-03-18
FI95771C (fi) 1996-03-25
JPH01102020A (ja) 1989-04-19
KR960009408B1 (en) 1996-07-19
HUT52368A (en) 1990-07-28
NZ226210A (en) 1990-04-26
PT88505B (pt) 1993-03-31
ES2040789T3 (es) 1993-11-01
EP0307904A1 (de) 1989-03-22
MX13023A (es) 1993-12-01
AU2236688A (en) 1989-03-23
IL87710A0 (en) 1989-02-28
ZA886873B (en) 1989-04-26
NO884134D0 (no) 1988-09-16
DK516888A (da) 1989-03-19
FI95771B (fi) 1995-12-15
FI884280A0 (fi) 1988-09-16
PT88505A (pt) 1988-10-01
CA1331341C (en) 1994-08-09
IE62990B1 (en) 1995-03-08
US4996058A (en) 1991-02-26
GR3007695T3 (fi) 1993-08-31
DK516888D0 (da) 1988-09-16
NO178095B (no) 1995-10-16
ATE85518T1 (de) 1993-02-15

Similar Documents

Publication Publication Date Title
FI884280A (fi) Menetelmä päällystetyn, hidastetun luovutuksen omaavan antomuodon valmistamiseksi
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
ES2060671T3 (es) Medicamento, producto dietetico y producto de higiene en forma de una composicion pulverulenta obtenida por adsorcion de principios activos en un azucar de disolucion rapida y procedimiento de obtencion de dicha composicion.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ES2035259T3 (es) Compuesto absorbente.
MX10086A (es) Un sistema para la administracion de substancias activas no solubles en agua y procedimiento para su preparacion.
NO153637C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat som er egnet for transdermal administrering av virkestoffer.
SE8803486L (sv) Dosform foer behandling av kardiovaskulaera sjukdomar
DE58902457D1 (de) Retardierte arzneiform und verfahren zu ihrer herstellung.
NO177376C (no) Fremgangsmåte for fremstilling av en farmasöytisk doseringsform basert på en tampongtrykkmetode
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
KR880002521A (ko) 약제 제형
JPS643123A (en) Remedy for skin inflammation
IT8721098A0 (it) Derivati della 1-benzene solfonil 2-oco 5-alchiltio pirrolidina, un loro procedimentodi preparazione e il loro impiegocome stostanze medicinali.
AR224929Q (es) Procedimiento para la preparacion de formas medicamentosas administrable por via oral,de liberacion uniforme e independiente del ph de una sustancia activa soluble en agua

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: NOVARTIS AG

FG Patent granted

Owner name: NOVARTIS AG

MA Patent expired